BRAF and neoplasm: As oncogenic drivers, one would expect that the primary tumors are dominated by tumor cell clones carrying the activating mutation, however, there are data indicating that this is not necessarily the case; heterogeneity both for mutant BRAF [2, 3] and NRAS [4] may occur in primary melanomas.